You are viewing: India Al in Clinical Trials Market analysis
Part of: AI in Clinical Trials Market (Global)

The India Al in Clinical Trials Market was valued at $15.72 Million in 2024 and projected to reach to $23.7 Million by 2029, representing a compound annual growth rate of 7.1%. India's AI in Clinical Trials market is poised for steady expansion as healthcare organizations recognize the operational efficiencies and cost savings AI technologies deliver.

India Al in Clinical Trials Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Al in Clinical Trials Market Trends and Insights

  • India is increasingly adopting artificial intelligence technologies to streamline clinical trial operations, enhance patient recruitment, and improve data management across the healthcare sector.
  • The market expansion in India reflects growing investments in healthcare infrastructure and the rising adoption of digital health solutions among pharmaceutical and contract research organizations (CROs). The 7.1% compound annual growth rate (CAGR) demonstrates India's moderate but consistent advancement in AI-driven clinical trial capabilities.
  • India's position as a global hub for clinical research, combined with cost-effective solutions and a large patient population, positions the country favorably for AI integration.
  • Between 2024 and 2029, India is expected to see increased deployment of AI algorithms for patient stratification, adverse event monitoring, and regulatory compliance, driven by both domestic and multinational pharmaceutical companies operating within India's regulatory framework..

Key Market Statistics

  • CAGR (2024-2029) 7.1% CAGR
  • Market Size, 2024 ~USD 15.72 Million
  • Forecast, 2029 ~USD 23.7 Million
  • Country India

India Al in Clinical Trials Market Overview

Market Valuation :

India's AI in Clinical Trials market is valued at $15.72 million in 2024, with a projected CAGR of 7.1% through 2029, reaching $23.7 million by forecast end.

Patient Recruitment Innovation :

Indian healthcare organizations are leveraging AI to enhance patient recruitment efficiency, reducing trial timelines and improving enrollment rates across diverse patient populations.

Data Management Advancement :

AI technologies are streamlining clinical trial data management in India, enabling real-time monitoring, reducing manual errors, and accelerating regulatory compliance processes.

Growing Healthcare Investment :

Increased investment in healthcare infrastructure and digital transformation initiatives across India are driving adoption of AI-powered clinical trial solutions among pharmaceutical and biotech companies.

India Al in Clinical Trials Market Dynamics

  • The country's large patient population, growing pharmaceutical sector, and increasing focus on clinical research infrastructure create favorable conditions for market growth.
  • Government initiatives promoting healthcare digitalization and rising collaborations between Indian CROs and global pharmaceutical companies are accelerating AI adoption. The 7.1% CAGR reflects India's emerging position as a clinical trial hub in Asia.
  • While growth trails the global 12.4% CAGR, India's market is expected to mature as regulatory frameworks evolve and awareness increases among trial sponsors.
  • Investment in AI capabilities for patient stratification, adverse event monitoring, and protocol optimization will remain key growth drivers through 2029..

Market Ecosystem

logo-mobile

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • India's AI in Clinical Trials market is valued at $15.72 million in 2024 and is forecast to grow to $23.7 million by 2029, representing a 7.1% CAGR.
    • India's cost-effective AI solutions and large patient population make the country an attractive destination for clinical trial innovation and digital health adoption.
    • AI adoption in India is accelerating for patient recruitment, data analytics, and regulatory compliance across pharmaceutical and CRO sectors.
    • India's growing healthcare infrastructure investments and digital transformation initiatives are key drivers supporting market expansion through 2029.

    Al in Clinical Trials Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment DRUG REPURPOSING (Function)
    Forecast Period 2024-2029
    Growth Rate CAGR of 12.4% from 2024 to 2029
    Largest Segment CLOUD-BASED SOLUTIONS (Deployment Mode)
    Market Size Base Year (Billions) ~USD 1.36 (2024)
    Revenue Forecast (Billions) ~USD 2.44 (2029)
    Segments Covered Offering, Function, Type, Phase, Deployment Mode, Indication, Technology, Application, End User

    India Al in Clinical Trials Market Report Segmentation

    9 segment dimensions are covered across the global market.

    By Offering

    • End-To-End Solutions
    • Niche Solutions
    • Services
    • Technology Providers

    By Function

    • Adverse Event Prediction & Detection
    • Data Management & Quality Control
    • Drug Repurposing
    • Patient Recruitment
    • Regulatory Compliance
    • Trial Design Optimization

    By Type

    • Deep Learning
    • Hybrid Cloud-Based Solutions
    • Multi Cloud-Based Solutions
    • Other Machine Learning Technologies
    • Patient Engagement & Retention
    • Patient Identification & Screening
    • Predictive Modeling
    • Private Cloud-Based Solutions
    • Public Cloud-Based Solutions
    • Reinforcement Learning
    • Risk Management
    • Site Optimization
    • Supervised Learning
    • Unsupervised Learning
    • Workflow Management

    By Phase

    • Phase I Clinical Trials
    • Phase Ii Clinical Trials
    • Phase Iii Clinical Trials
    • Phase Iv Clinical Trials

    By Deployment Mode

    • Cloud-Based Solutions
    • On-Premises Solutions

    By Indication

    • Cardiovascular Diseases
    • Immunological Diseases
    • Immunology Diseases
    • Infectious Diseases
    • Metabolic Diseases
    • Neurological Diseases
    • Oncology
    • Other Diseases

    By Technology

    • Computer Vision
    • Machine Learning
    • Natural Language Processing
    • Other Technologies
    • Robotic Process Automation

    By Application

    • Biomarkers
    • Cell & Gene Therapy
    • Gene & Cell Therapy
    • Medical Devices & Diagnostics
    • Regenerative Medicines

    By End User

    • Contract Research Organizations
    • Healthcare Providers
    • Medical Device Manufacturers
    • Pharmaceutical & Biopharmaceutical Companies
    • Research Institutes & Laboratories

    INDIA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030

    Segment202220232024202520262027202820292030CAGR (%)
    CONTRACT RESEARCH ORGANIZATIONS3.844.154.474.835.215.626.056.527.027.8
    HEALTHCARE PROVIDERS5.65.946.36.677.077.497.938.398.885.9
    MEDICAL DEVICE MANUFACTURERS4.575.025.516.056.647.287.988.759.589.7
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES15.116.1517.2618.4319.6821.0122.4223.9125.496.7
    RESEARCH INSTITUTES & LABORATORIES7.137.778.469.2110.0210.911.8512.8813.998.7
    TOTAL36.2439.024245.248.6252.2956.2360.4564.977.5

    Target Audience

    • Pharmaceutical & Biotech Companies : Indian and multinational pharma firms need market intelligence to optimize clinical trial operations, reduce costs, and accelerate drug development timelines through AI adoption in India.
    • Clinical Research Organizations (CROs) : Indian and global CROs require detailed market data to enhance service offerings, identify technology investment priorities, and strengthen competitive positioning in India's growing trial market.
    • Healthcare Technology Vendors : AI and software solution providers need India-specific market insights to develop localized products, understand customer requirements, and establish distribution channels in the Indian healthcare sector.
    • Healthcare Investors & Consultants : Investment firms and management consultants need validated market data to assess India's clinical trial AI sector viability, identify portfolio opportunities, and guide client expansion strategies.
    • Healthcare Policy & Regulatory Bodies : Government agencies and regulatory authorities require market intelligence to inform healthcare digitalization policies, clinical trial guidelines, and AI governance frameworks specific to India.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for India's AI in Clinical Trials market with verified CAGR projections, enabling accurate financial forecasting and investment decision-making for regional expansion.
    • Competitive Landscape Intelligence : Understand India-specific market dynamics, key players, and adoption patterns to identify competitive positioning opportunities and strategic partnerships within the Indian clinical trial ecosystem.
    • Regulatory & Implementation Insights : Access India-focused analysis of regulatory requirements, compliance frameworks, and implementation best practices for deploying AI solutions in Indian clinical trial operations.
    • Investment & Growth Opportunity Assessment : Evaluate India-specific growth drivers, market gaps, and emerging opportunities to prioritize resource allocation and identify high-potential segments within the $23.7M forecasted market.
    • Stakeholder Strategy Development : Leverage India market insights to develop targeted go-to-market strategies for pharmaceutical companies, CROs, healthcare providers, and technology vendors operating in the Indian market.

    Frequently asked questions

    What is the current market size of AI in Clinical Trials in India?

    India's AI in Clinical Trials market was valued at $15.72 million in 2024 and is expected to reach $23.7 million by 2029.

    What is the projected growth rate for AI in Clinical Trials in India?

    India's AI in Clinical Trials market is projected to grow at a compound annual growth rate (CAGR) of 7.1% from 2024 to 2029.

    Why is India becoming a hub for AI-driven clinical trials?

    India offers cost-effective AI solutions, a large patient population, established CRO infrastructure, and increasing healthcare digitalization, making it attractive for clinical trial innovation.

    What AI applications are most prevalent in India's clinical trials market?

    India is seeing increased adoption of AI for patient recruitment optimization, adverse event monitoring, data management, patient stratification, and regulatory compliance automation.

    Which sectors are driving AI adoption in India's clinical trials?

    Pharmaceutical companies, contract research organizations (CROs), and healthcare institutions in India are the primary drivers of AI adoption in clinical trial operations.

    RESEARCH METHODOLOGY

    The study involved significant activities to estimate the current size of the AI in clinical trials market. Exhaustive secondary research was done to collect information on the AI in clinical trials market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in clinical trials market.

    Secondary Research

    This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in clinical trials solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

    Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in clinical trials vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

    Primary Research

    In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in clinical trials market.

    After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in clinical trials solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

    In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

    Breakdown of Primary Participants:

    AI in Clinical Trials Market

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in clinical trials market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research.
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
    AI in Clinical Trials Market

    Data Triangulation

    After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    The AI in clinical trials market refers to the utilization of artificial intelligence-based tools to improve the different phases as well as steps of clinical research process activity such as trial development, enrolment of patients, data management and analysis and therapeutic monitoring. Al assists in accomplishing such tasks by automating the collection of data, enhancing the efficiency of patient matching and improving prediction of outcomes of trials which in turn helps in reducing the timeline and cost associated with these processes. This allows for a clearer understanding of large amounts of information, for example, within patient charts or genome information, so that the appropriate information is available for making decisions for particular trials. Clinical trials become highly efficient, cheaper, and more precise with the integration of Al technologies into the processes which significantly helps in drug development reducing the waiting time and the success rate improves. With more and more applications of AI in the healthcare sector, this healthcare services market is projected to grow as there will be a rise in the need for improved clinical research within a short turnaround time.

    Stakeholders

    • Pharmaceutical and Biotechnology Companies
    • Contract Research Organizations (CROs)
    • Technology and AI Companies
    • Regulatory Authorities
    • Hospitals and Healthcare Providers
    • Patients and Patient Advocacy Groups
    • Clinical Trial Investigators and Site Coordinators
    • Data Management and Analytics Firms
    • Academic Institutions and Research Organizations
    • Investors and Venture Capital Firms
    • Clinical Trial Software Providers
    • Ethics Committees and Institutional Review Boards (IRBs)
    • Insurance Companies

    Report Objectives

    • To define, describe, and forecast the AI in clinical trials market based on offering, function, phase, deployment mode, indication, technology, application, end user, and region.
    • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
    • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
    • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
    • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
    • To profile the key players and comprehensively analyze their market sizes and core competencies.
    • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally.

     

    Get the Full AI in Clinical Trials Market Report

    Full forecast, segment splits, and company analysis for all AI in Clinical Trials Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status